Abstract. Inhibitors of angiogenesis are potential anti-cancer agents in that they deprive tumors of the blood necessary for growth and metastasis. The anti-angiogenic efficacy of tinzaparin, a known anticoagulant low molecular weight heparin (LMWH), was examined in vitro in endothelial cell tube formation assay and in vivo in the chick chorioallantoic membrane model. The observed anti-angiogenic effects of tinzaparin were shown to be dose-related and dependent on the relatively higher molecular weight tinzaparin fragments. These experiments demonstrated that tinzaparin is a potent inhibitor of angiogenesis (ED 90-100 range, 0.05-0.1 mg) regardless of the angiogenic factor and suggest that its effect is mediated via cellular release of tissue factor pathway inhibitor (TFPI). This was evident by the reversal of either tinzaparin or r-TFPI anti-angiogenesis efficacy by a specific monoclonal TFPI antibody. The ED 90-100 for the inhibition of angiogenesis for r-TFPI ranged from 0.01 to 0.03 mg in the chorioallantoic membrane model regardless of the proangiogenic factor. In addition, either tinzaparin or r-TFPI inhibited the growth of colon carcinoma tumors, human fibrosarcoma tumors, and human lung carcinoma in the chorioallantoic membrane tumor implant model. Thus, the LMWH tinzaparin, in addition to its anticoagulant effects, may offer important benefits in treatment of cancer and other disorders supported by pathologic angiogenesis.
Introduction
Angiogenesis is an essential feature of normal biologic processes, such as growth, development, reproduction, and repair of damaged tissue (1) (2) (3) . Endogenous promoters and inhibitors regulate the complex process of angiogenesis (2) . The later stages involve proliferation and organization of endothelial cells (ECs) into tube-like structures. Vascular endothelial growth factor (VEGF) and fibroblast growth factor-2 (FGF-2) are important promoters of this process; these promoters exert their effects by binding to cell surface receptors. Human ECs in culture can form tube-like structures with lumens, and they represent an in vitro model system for the study of the angiogenesis process. Pathologic angiogenesis, which may occur when a normal control mechanism is defective, contributes to the growth and metastasis of tumors (3) , as well as to inflammatory and certain ocular diseases.
Drugs that inhibit angiogenesis may be effective in the treatment of these human disorders (3) . The mechanisms by which anti-angiogenic drugs exert their effects can vary widely, acting on different points in the complex process of tumor angiogenesis. Potential points of control include blocking the action of endogenous stimulators; inhibiting the growth, migration, and tube formation of ECs; and inhibiting the turnover of the capillary basement membrane (1) . The role of heparin in angiogenesis modulation and its potential anticancer effect has been previously described, but without clear delineation of its pro-versus anti-angiogenic effect, as well as its mechanism of action (4, 5) .
Tinzaparin, a low molecular weight heparin (LMWH), has an average molecular weight of 6.5 kDa; it is produced by enzymatic degradation of heparin and has proven efficacy in the treatment of deep vein thrombosis and pulmonary embolism (6,7). Tinzaparin's antithrombotic activity is mediated by binding to microvascular tissues and activation of antithrombin III, a potent anticoagulant (8) . Tinzaparin also causes release of tissue factor pathway inhibitor (TFPI), an important endogenous inhibitor of TF/VIIa (9). Several clinical trials have shown improved survival of cancer patients following heparin therapy (10) (11) (12) . In one double-blind, multicenter clinical trial, tinzaparin was shown to be effective in the treatment of proximal deep vein thrombosis in a patient population that included a large percentage of cancer patients (6) . These clinical data suggest that tinzaparin may have some benefit in the treatment of cancer patients. The present study was undertaken to elucidate the mechanisms through which tinzaparin may affect tumor angiogenesis and to assess its efficacy in inhibiting the angiogenesis processes.
Materials and methods
Endothelial tube formation assay. Human umbilical vein ECs (HUVECs) were obtained from Clonetics (Walkersville, MD, USA). Cells were grown to 80-90% confluence in endothelial growth medium (EGM) containing recombinant human endo-thelial growth factor (hEGF; 10 ng/ml), hydrocortisone (1 mg/ ml), gentamicin (50 mg/ml), amphotericin-B (50 µg/ml), blood brain extract (0.012 mg/ml), and 2% fetal bovine serum equilibrated with 95% air and 5% CO 2 at 37˚C (13) .
The basic form of FGF-2 was purchased from Gibco BRL (Gaithersburg, MD, USA) and R&D Systems (Minneapolis, MN, USA). Cells were serially passed in cell culture flasks coated with 0.2% gelatin (Sigma, St. Louis, MO, USA), and confluent cultures between the third and sixth passages were washed with Hank's balanced salt solution, harvested with 0.025% trypsin and 0.01% ethylenediaminetetraacetic acid, and counted by hemocytometer. HUVECs were re-suspended in 24-well plates coated with Matrigel matrices or directly on 96-well cell culture plates. Matrigel growth factor reduced (Becton Dickinson, Bedford, MA, USA) was thawed overnight at 4˚C. Then, 250 µl aliquots were placed into the wells of a cold 24-well plate, and polymerization was promoted by 30 min incubation at 37˚C. After counting, ECs were plated at 40,000 cells/well in endothelial basal medium (EBM) containing FGF-2 (50 ng/ml) at an initial volume of 125 µl per well. Following 1-2 h incubation at 37˚C, 5% CO 2 , and 95% humidity, 125 µl samples with tinzaparin dissolved in EBM media were added. Plates were incubated overnight at 37˚C in 5% CO 2 at 95% humidity. For visualization, the medium was removed, and cells were fixed and stained using a modified Hema 3 Stain kit (Fisher, Swedesboro, NJ, USA).
Chorioallantoic membrane angiogenesis model. Ten-day old embryos were purchased from Spafas, Inc. (Preston, CT, USA) and incubated at 37˚C with 55% humidity. A small hole was punctured in the shell concealing the air sac; a second hole was punctured in the shell on the broad side of the egg directly over the avascular portion of the embryonic membrane, as observed during candling (14) . A false air sac was created beneath the second hole by the application of negative pressure to the first hole, which caused the chorioallantoic membrane (CAM) to separate from the shell. A window, approximately 1.0 cm 2 , was cut in the shell over the dropped CAM with the use of a small crafts grinding wheel (Dremel, Division of Emerson Electric Company, Racine, WI, USA) that allowed direct access to the underlying CAM. Filter disks of #1 filter paper (Whatman International, UK) were soaked in 3 mg/ml cortisone acetate (Sigma) in a solution of 95% ethanol and air dried under sterile conditions. FGF-2 or other angiogenic factors were used to grow vessels on the CAMs of 10-day-old chick embryos. Sterile filter disks with FGF-2 dissolved in phosphate buffered saline (PBS; pH 7.4 at 1 µg/ml) were placed on growing CAMs (14) . After 24 h, control or test compounds were added topically or by intravenous injection. Different concentration ranges in 25 µl of the LMWH fractions, r-TFPI, tinzaparin, or 25 µl of buffered saline were applied to the growth-factor-saturated filter 24 h later ( Fig. 1 ).
Microscopic analysis of CAM sections. CAM tissue directly beneath the FGF-2-saturated filter disk was resected from embryos treated 48 h previously with compounds or controls. Tissues were washed three times with PBS. Sections were placed in a 35-mm Petri dish obtained from Nalge Nunc (Rochester, NY, USA) and examined under an SV6 stereomicroscope from Karl Zeiss (Thornwood, NY, USA) at x50 magnification. Digital images of CAM sections adjacent to filters were collected using a 3-CCD color video camera system from Toshiba America (New York, NY, USA) and were analyzed with the Image-Pro Plus software from Media Cybernetics (Silver Spring, MD, USA). The number of vessel branch points contained in a circular region equal to the area of a filter disk was counted for each section (14) . Percent inhibition data are expressed as the quotient of the experimental value minus the negative control value, divided by the difference between the positive control value and the negative control value.
Endothelial TFPI release assay. HUVEC TFPI is synthesized and constitutively secreted by ECs, and a major portion of intravascular TFPI is stored in association with ECs. TFPI has valuable effects on various cellular and vascular events that might broaden the efficacy and utility of heparin and derivatives. The effect of heparin molecular weight fractions ranging from 1,700 to 12,000 kDa and different LMWHs on the release of TFPI from HUVECs was determined.
CAM tumor implant model. Ten million tumor cells were placed on the surface of each CAM (7-day-old embryo) and were cultured for 1 week. The resulting tumors were excised and cut into 50-mg fragments. These fragments were placed on additional CAMs and treated topically the following day with tinzaparin, r-TFPI, or PBS (Fig. 2) . Seven days later, CAMs were excised from the egg, and the number of blood vessels entering the tumors was counted (as vessel branch points). Each treatment group incorporated at least ten tumors per experiment. Tumors were then excised from the egg, and tumor weights were determined for each CAM. Data are presented as mean tumor weight per treatment group ± SEM. Statistical analysis was performed using the Student t-test, p<0.05.
Results

LMWH and TFPI inhibit EC tube formation.
A pivotal stage of angiogenesis is the formation of tube-like structures from ECs (1), a process that is mediated by cytokines binding to EC surface receptors (15) . In this investigation we used an in vitro assay with cultured HUVECs capable of forming tube-like structures (13) . The results show that FGF-2 (16) stimulates EC tube cell formation. Addition of tinzaparin reverses the FGF-2 effect in a dose-related fashion; tinzaparin (0.5 µg) completely reverses the FGF-2 effect to about the same level as seen in the PBS control (Table I ). The effect of r-TFPI was also examined using the same assay. Like tinzaparin, r-TFPI at 12.5 ng significantly inhibited formation of EC tube formation induced by FGF-2. In contrast, a potent and specific anti-Xa (r-TAP) resulted in marginal effect on FGF-2-induced EC tube formation as compared with tinzaparin (Table I) .
Reversal of the inhibitory efficacy of tinzaparin on EC tube formation by anti-TFPI.
The inhibitory efficacy of tinzaparin or r-TFPI on FGF2-induced EC tube formation was totally reversed by a specific monoclonal TFPI antibody (Table I) . Similar data were shown for this antibody in reversing the inhibitory effect of tinzaparin or r-TFPI on TF/VIIa-induced EC tube formation (data not shown). 
LMWH and TFPI inhibit angiogenesis in the CAM model.
The anti-angiogenic effect of tinzaparin was further investigated utilizing a chick CAM assay (14) . In this assay, the number of new blood vessel branch points that form following treatment provides a size-independent measure of the sprouting of new vessels that occurs during angiogenesis. Treatment with FGF-2 promoted formation of new blood vessel branch points by 2-to 3-fold above baseline. However, CAM tissue treated with FGF-2 and tinzaparin exhibited reversal of FGF-2-induced angiogenesis (Fig. 3) . This anti-angiogenic reversal was dosedependent (Fig. 3) . Similar results were shown with r-TFPI in inhibiting FGF-2-induced angiogenesis. Treatment of CAM tissue with lipopolysaccharide, another angiogenesis promoter (12) , also promoted formation of new blood vessel branch points. The reversal of lipopolysaccharide-induced angiogenesis was also observed with r-TFPI or tinzaparin (Table II) . Additionally, angiogenesis mediated by other angiogenic factors, such as VEGF or tissue factor, was inhibited by tinzaparin (Table II) . Similar anti-angiogenesis effects were demonstrated with r-TFPI in inhibiting VEGF and tissue factorinduced angiogenesis (Table II) .
LMWH-induced TFPI release from human ECs.
In an effort to further characterize and evaluate tinzaparin's effect on angiogenesis and TFPI release, different molecular weight fractions of tinzaparin (ranging from 1,700 to 12,623 Da) were obtained by gel filtration. These various molecular weight fragments were evaluated for their ability to release TFPI from ECs and their ability to inhibit angiogenesis. Results from these experiments revealed that relatively higher molecular weight tinzaparin fragments were more effective in releasing TFPI from ECs in a concentrationdependent fashion and in inhibiting FGF-2-induced angiogenesis in the CAM model (Table III) . Table I . Inhibition of FGF-2-induced EC tube formation by LMWH but not by anti-Xa.
a -------------------------------------------------
Mean % inhibition of EC tube formation Agents tested induced by FGF-2 ± SD  ----------------------------------------------- 
Mediation by TFPI. EC, endothelial cell; FGF-2, fibroblast growth factor-2; LMWH, low molecular weight heparin; TAP, tick anticoagulant peptide; TFPI, tissue factor pathway inhibitor. LMWH and TFPI inhibit tumor growth in the CAM tumor implant model. In order to evaluate the implications of tinzaparin's anti-angiogenic and TFPI-releasing properties, a series of experiments was performed that examined the growth of colon carcinoma, human fibrosarcoma (HT-1080) tumor growth, and lung carcinoma growth in the CAM model. In all cases, either tinzaparin or r-TFPI decreased the tumor growth observed in these experimental models (Table IV) .
In addition to its anti-angiogenic properties, tinzaparin also exhibited potent anti-tumor activity in a variety of experimental models, including colon carcinoma tumor, human fibrosarcoma tumor, and human lung carcinoma in the CAM model. These data are consistent with the view that coagulation and fibrinolytic pathways are capable of influencing malignant progression and that anticoagulant drugs (such as tinzaparin) could therefore be hopeful treatments for cancer patients (17) .
Discussion
Angiogenesis is a highly regulated process that is critical for development and wound healing in the adult organism. Although placid for the most part, when angiogenesis becomes active, it can support the induction of a variety of human disorders, including cancer, inflammatory disease, and ocular disease. Thus, the discovery of pharmacological agents that possess anti-angiogenic properties could be therapeutically beneficial. The results of these experiments indicate that tinzaparin, an LMWH used to treat venous thrombosis, has significant potential as an anti-angiogenic drug. The potent anti-angiogenic effect of tinzaparin observed in the present experiments appears to be mediated by induction of TFPI release, an endogenous inhibitor of angiogenesis, since tinzaparin's anti-angiogenic activity in a variety of in vitro and in vivo models appears to be synchronized with its ability to release TFPI.
In the present experiments, the higher molecular weight tinzaparin fragments exhibited an increased anti-angiogenic potency, as well as an increased ability to release r-TFPI. These data further support the specificity of tinzaparin's antiangiogenic effect, as well as the critical linkage with TFPI release. In contrast to the earlier notion that the hexasaccharide moiety within heparin is responsible for the anti-tumor efficacy (4), this investigation revealed an optimal structurefunction anti-angiogenesis and TFPI release from EC at heparin molecular weight fractions ranging from 6 to 8 kDa. In reality, LMWH fractions in the range of hexasaccharide have minimal TFPI release and are associated with minimal anti-angiogenesis efficacy. As Fareed and colleagues (18) have noted, different manufacturing processes for the various LMWHs result in different physical and chemical compositions that ultimately translate into different biological activities. Because tinzaparin's molecular weight and sulfation profiles are slightly higher than other LMWHs, it might be particularly suited for further investigation as an anti-neoplastic agent. ONCOLOGY REPORTS 12: 683-688, 2004 Table II. Anti-angiogenesis efficacy of tinzaparin or r-TFPI in inhibiting different angiogenesis factor-induced angiogenesis in the CAM model. 
CAM, chorioallantoic membrane; FGF-2, fibroblast growth factor-2; LPS, lipopolysaccharide; TF, tissue factor; TFPI, tissue factor pathway inhibitor; VEGF, vascular endothelial growth factor. Table III . Effects of heparin molecular weight fractions (HMWFs) at 10 µg on TFPI release from HUVECs and on FGF-2-induced angiogenesis in the CAM model.
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Mean TFPI released (ng/1x10 5 cells/2 h) ± SD, n=3. Mean % inhibition of angiogenesis in the CAM model, n=8/group. CAM, chorioallantoic membrane; FGF-2, fibroblast growth factor-2; HUVECs, human umbilical vein endothelial cells; TFPI, tissue factor pathway inhibitor. Table IV . Effect of tinzaparin or r-TFPI on tumor growth in the CAM tumor implant model. Tumor type  Control  Tinzaparin  r-TFPI  -------------------------------------------------Colon  72±8  2 -
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